1. Home
  2. TIL vs ASRT Comparison

TIL vs ASRT Comparison

Compare TIL & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Instil Bio Inc.

TIL

Instil Bio Inc.

N/A

Current Price

$9.04

Market Cap

74.7M

Sector

Health Care

ML Signal

N/A

Logo Assertio Holdings Inc.

ASRT

Assertio Holdings Inc.

N/A

Current Price

$11.57

Market Cap

76.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TIL
ASRT
Founded
2018
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
74.7M
76.0M
IPO Year
2021
2004

Fundamental Metrics

Financial Performance
Metric
TIL
ASRT
Price
$9.04
$11.57
Analyst Decision
Buy
Strong Buy
Analyst Count
3
1
Target Price
$125.00
$35.00
AVG Volume (30 Days)
41.1K
29.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
52.54
95.07
EPS
N/A
N/A
Revenue
N/A
$124,961,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.67
$0.51
52 Week High
$42.75
$12.95

Technical Indicators

Market Signals
Indicator
TIL
ASRT
Relative Strength Index (RSI) 58.14 53.65
Support Level $8.14 $11.05
Resistance Level $9.81 $12.75
Average True Range (ATR) 0.64 0.45
MACD 0.05 -0.17
Stochastic Oscillator 58.68 52.41

Price Performance

Historical Comparison
TIL
ASRT

About TIL Instil Bio Inc.

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

About ASRT Assertio Holdings Inc.

Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.

Share on Social Networks: